Celalettin Ustun

Trials

Studies that name Celalettin Ustun as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:09 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06917911 · Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  National Cancer Institute (NCI) · recruiting · Core Binding Factor Acute Myeloid Leukemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Alliance for Clinical Trials in Oncology Member Site Core
  U10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026
  Named on NCT06917911